Brevan Howard Capital Management LP Buys 8,960 Shares of Hologic, Inc. (NASDAQ:HOLX)

Brevan Howard Capital Management LP raised its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 85.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,436 shares of the medical equipment provider's stock after purchasing an additional 8,960 shares during the period. Brevan Howard Capital Management LP's holdings in Hologic were worth $1,401,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC raised its position in shares of Hologic by 156.3% in the 4th quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider's stock valued at $31,000 after purchasing an additional 261 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Hologic by 79.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider's stock valued at $42,000 after acquiring an additional 260 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 159 shares during the period. Smithfield Trust Co grew its position in Hologic by 160.0% during the fourth quarter. Smithfield Trust Co now owns 650 shares of the medical equipment provider's stock valued at $45,000 after purchasing an additional 400 shares in the last quarter. Finally, Sound Income Strategies LLC bought a new position in Hologic during the fourth quarter valued at approximately $60,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently weighed in on the company. Citigroup cut their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating for the company in a research report on Tuesday, March 4th. Royal Bank of Canada cut their price target on Hologic from $75.00 to $70.00 and set a "sector perform" rating for the company in a report on Friday, May 2nd. Needham & Company LLC reissued a "hold" rating on shares of Hologic in a report on Friday, May 2nd. Morgan Stanley cut their target price on Hologic from $77.00 to $65.00 and set an "equal weight" rating for the company in a research note on Monday. Finally, William Blair reaffirmed an "outperform" rating on shares of Hologic in a research report on Thursday, February 6th. Twelve equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Hologic has an average rating of "Hold" and an average price target of $79.85.

Insiders Place Their Bets

In other Hologic news, Director Martin D. Madaus bought 5,445 shares of Hologic stock in a transaction dated Wednesday, May 7th. The shares were bought at an average price of $55.24 per share, with a total value of $300,781.80. Following the purchase, the director now owns 5,445 shares of the company's stock, valued at $300,781.80. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 1.88% of the company's stock.

Hologic Price Performance

HOLX stock traded up $0.56 during midday trading on Friday, reaching $56.74. 3,258,934 shares of the company's stock traded hands, compared to its average volume of 2,090,002. The company has a 50-day simple moving average of $59.43 and a two-hundred day simple moving average of $68.34. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 1-year low of $51.90 and a 1-year high of $84.67. The company has a market cap of $12.73 billion, a price-to-earnings ratio of 17.90, a PEG ratio of 2.14 and a beta of 0.54.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share for the quarter, beating analysts' consensus estimates of $1.02 by $0.01. The company had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 19.72% and a net margin of 18.42%. The firm's quarterly revenue was down 1.2% compared to the same quarter last year. During the same period last year, the company posted $1.03 earnings per share. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.